Ipratropium bromide

Indication: Asthma

INN: Ipratropium bromide

Medicine type: Chemical agent

List type: Core

Formulations: Respiratory > Inhalation > aerosol: 20 µg per dose

EML status history:
- First added in 1997 (TRS 882)
- Changed in 2007 (TRS 950)

Sex: All

Age: Adolescents and adults

Therapeutic alternatives: The recommendation is for this specific medicine

Patent information: Patents have expired in most jurisdictions

Wikipedia: Ipratropium bromide

DrugBank: Ipratropium (Ipratropium bromide)

Summary of evidence and Expert Committee recommendations:

The EMLc Subcommittee did not endorse the inclusion of ipratropium bromide on the EMLc as there is uncertainty as to its role in childhood asthma and should be reviewed.